Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

MCM7 amplification and overexpression are associated with prostate cancer progression


The genomic DNA profiles of prostate cancers with aggressive features were compared to the profiles of matched normal DNA to identify genes that are selectively amplified in the cancer cells. One of the identified genes, MCM7, which is a component of the DNA replication licensing complex, has been studied extensively both at the DNA and protein levels in human prostate tissues. Approximately half of the prostate cancer specimens studied showed MCM7 gene amplification, and 60% of the aggressive prostate cancer specimens had increased MCM7 protein expression. Amplification or overexpression of MCM7 was significantly associated with relapse, local invasion and a worse tumor grade. Constitutive expression of MCM7 in a human prostate cancer cell line, DU145, resulted in markedly increased DNA synthesis and cell proliferation compared to vector-only controls, and an increased cell invasion in vitro. Indeed, MCM7 overexpression produced primary tumors 12 times larger than vector-only controls and resulted in a rapid demise of mice bearing those tumors. These studies implicate MCM7, and the DNA replication licensing gene family, in prostate cancer progression, growth and invasion.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3


  • Aparicio OM, Weinstein DM, Bell SP . (1997). Cell 91: 59–69.

  • Blow JJ, Hodgson B . (2002). Trends Cell Biol. 12: 72–78.

  • Brake T, Connor JP, Petereit DG, Lambert PF . (2003). Cancer Res. 63: 8173–8180.

  • Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I et al. (2003). Oncogene 22: 1247–1252.

  • Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F et al. (2004). Oncogene 23: 2484–2498.

  • Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS et al. (2003). Genomics 81: 260–269.

  • Edwards MC, Tutter AV, Cvetic C, Gilbert CH, Prokhorova TA, Walter JC . (2002). J. Biol. Chem. 277: 33049–33057.

  • Fujita M, Yamada C, Goto H, Yokoyama N, Kuzushima K, Inagaki M et al. (1999). J. Biol. Chem. 274: 25927–25932.

  • Ishimi Y . (1997). J. Biol. Chem. 272: 24508–24513.

  • Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). CA Cancer J. Clin. 55: 10–30.

  • Jiang W, McDonald D, Hope TJ, Hunter T . (1999). EMBO J. 18: 5703–5713.

  • Jing L, Liu L, Yu YP, Dhir R, Acquafondada M, Landsittel D et al. (2004). Am. J. Pathol. 164: 1799–1806.

  • Kukimoto I, Aihara S, Yoshiike K, Kanda T . (1998). Biochem. Biophys. Res. Commun. 249: 258–262.

  • Labib K, Kearsey SE, Diffley JF . (2001). Mol. Biol. Cell 12: 3658–3667.

  • Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T . (2002). Genes Chromosomes Cancer 35: 66–73.

  • Lu ZH, Xu H, Leno GH . (1999). Mol. Biol. Cell 10: 4091–4106.

  • Luo JH, Yu YP . (2003). Expert Rev. Mol. Med. 2003: 1–26.

  • Pacek M, Walter JC . (2004). EMBO J. 23: 3667–3676.

  • Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG . (2004). J. Clin. Pathol. 57: 1057–1062.

  • Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J et al. (2003). Am. J. Pathol. 162: 763–770.

  • Pasion SG, Forsburg SL . (1999). Mol. Biol. Cell 10: 4043–4057.

  • Romanowski P, Madine MA, Laskey RA . (1996). Proc. Natl. Acad. Sci. USA 93: 10189–10194.

  • Wolter H, Trijic D, Gottfried HW, Mattfeldt T . (2002). Eur. Urol. 41: 328–334.

  • Xue WC, Khoo US, Ngan HY, Chan KY, Chia PM, Tsao SW et al. (2003). Histopathology 43: 485–490.

  • Yoshida K, Inoue I . (2003). FEBS Lett. 553: 213–217.

Download references


We thank Chris Szakulski for manuscript preparation. This work is supported by grants from National Cancer Institute to GM (1UO1CA88110-01) and to JHL (R01 CA098249), and John Rangos Foundation for Enhancement of Research in Pathology.

Author information

Authors and Affiliations


Corresponding author

Correspondence to J-H Luo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ren, B., Yu, G., Tseng, G. et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25, 1090–1098 (2006).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


This article is cited by


Quick links